News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Particle Sciences and Absorption Systems Form Relationship to Offer their Clients Enhanced Services



7/13/2011 5:43:54 AM

BETHLEHEM, Pa., July 12, 2011/PRNewswire/ -- Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, and Absorption Systems, a leading provider of pre-clinical pharmacokinetic services, announced today that the two companies are working together to provide their clients with enhanced drug development services by integrating pre-clinical pharmacokinetic data into the dosage form development scheme.

According to Robert Lee, Ph.D., Particle Sciences' Vice President Pharmaceutical Development, "Particle Sciences has always had a methodical approach to drug product development. Dosage form design is best done when informed by the in vivo solubility, permeability and metabolism of the drug. This is true for oral drug products as well as other routes of administration. Absorption Systems has put in place a scaled in vitro / ex vivo / in vivo approach to obtaining this data, which lends itself to our needs. For those clients that desire it, Particle Sciences can integrate this data stream into our drug product development plan. Ultimately, this should prove to be a cost-effective way to drive efficiency and minimize time to the clinic."

Chris Bode, Ph.D., Vice President Scientific & Corporate Communications at Absorption Systems, adds that "Our portfolio includes a number of physicochemical and biological tests that can make formulation development a more rational and efficient process. Particle Sciences is a leader in drug formulation and manufacturing, and we are very pleased that they are leveraging our toolset in their efforts. I believe this is consistent with their overall innovative and comprehensive approach to drug product development".

Absorption Systems, founded in 1996, assists pharmaceutical and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. The CellPort Technologies® platform, a suite of human cell-based test systems for drug transporter characterization, exemplifies Absorption Systems' commitment to innovation and is soon to be an industry assay standard for in vitro drug interaction assessment. Absorption Systems has facilities near Philadelphia, PA, and San Diego, CA, and serves customers throughout the world. For information on the company's comprehensive contract services and applied research programs, please visit www.absorption.com.

Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on emulsions, gels, particulates and drug/device combination products with additional specialized capabilities in topical and mucosal drug delivery. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com, email info@particlesciences.com or contact us at (610) 861- 4701 for information.

Contact: Maureen Mattera Cochran
1-610-861-4701
mcochran@particlesciences.com

SOURCE Particle Sciences Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES